article thumbnail

CDSCO releases draft guidance document on stability studies of IVD Medical Devices

AuroBlog - Aurous Healthcare Clinical Trials blog

The Central Drugs Standard Control Organisation (CDSCO) has released a draft guidance document on stability studies of In-vitro Diagnostic Medical Device (IVDMD) to aid manufacturers in the preparation of premarket review documents for the import or manufacturing license applications.

In-Vitro 241
article thumbnail

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pharmaceutical Technology

This approach to vaccination offers many advantages to developers, including quick development, high potency, a favorable safety profile, and the potential for cost-effective manufacturing. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. Single- and multi-nation funding opportunities flooded in.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

High risk, high reward – the future of CAR-T therapy in CLL

Pharmaceutical Technology

Autologous CAR-T therapy does not easily lend itself to treating CLL, as it relies on extracting functional T-cells from the patient’s blood and genetically modifying them in vitro. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.

In-Vitro 279
article thumbnail

What Should IVD Manufacturers Look for When Selecting a Lab Testing Partner?

XTalks

In vitro diagnostics, or IVD, is a field where precision, reliability and robust partnerships propel advancement. The collaboration between IVD manufacturers and lab testing partners is central to precise and efficient diagnostic processes. But why should IVD manufacturers choose Quest Diagnostics as one of these partners?

article thumbnail

Bioprinting technology combined with artificial intelligence allows high quality in vitro models

Medical Xpress

In the process of organoid manufacturing, bioprinting technology can not only facilitate the creation and maintenance of complex biological 3D shapes and structures, but also allow for standardization and quality control during production.

article thumbnail

Top 30 New Medical Devices of 2024

XTalks

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.

article thumbnail

Testing Facility Called “Game Changer” in Regenerative Medicine

Pharma Mirror

The Test Bed utilizes Cytocentric principles, an innovative philosophy of putting the needs of the vulnerable cells front and center while growing and manipulating them in vitro. By eliminating the fluctuations and suboptimal transients caused by.

Medicine 130